Press Releases

Date Title
May 17, 2022 Chimerix to Present at H.C. Wainwright Global Investment Conference
DURHAM, N.C. , May 17, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Sherman , Chief Executive Officer, will present a
May 16, 2022 Chimerix Reports First Quarter 2022 Financial Results and Provides Operational Update
– Receiving up to $337.5 Million plus Royalties for Sale of Worldwide Rights of TEMBEXA to Emergent BioSolutions – – Initiation of Phase 3 Randomized Study of ONC201 in H3 K27M Mutant Glioma Expected in 2022 – – DSTAT Development Program Terminated; Resources Focused on Imipridone Platform – –
May 16, 2022 Chimerix Announces Sale of TEMBEXA to Emergent BioSolutions for up to $337.5 Million plus Royalties
– $225 Million in Upfront Proceeds Secures Substantial Capital to Fund Operations and Allows for Participation in Future Economics – – Transaction Allows for Focus on Development Pipeline – – Positions TEMBEXA with Leading Global Biodefense Partner to Maximize Long Term Value – DURHAM, N.C.
May 12, 2022 Chimerix to Participate in Maxim Group Panel Discussion
DURHAM, N.C. , May 12, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Josh Allen , Ph.D., Chief Technology Officer of
May 09, 2022 Chimerix to Report First Quarter 2022 Financial Results and Provide an Operational Update on May 16, 2022
DURHAM, N.C. , May 09, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that it will host a live conference call and audio webcast
Mar 01, 2022 Chimerix Reports Fourth Quarter and Year End 2021 Financial Results and Provides Operational Update
– TEMBEXA RFP Response Submitted and Under Review with BARDA – – Pre-Clinical CMX521 Data Accepted for Late Breaking Oral Presentation at International Conference on Antiviral Research – – ONC201 Program Remains on Track – – Conference Call at 8:30 a.m. ET Today – DURHAM, N.C.
Feb 28, 2022 Chimerix to Present at Cowen and Company 42nd Annual Health Care Conference
DURHAM, N.C. , Feb. 28, 2022 (GLOBE NEWSWIRE) -- Chimerix  (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Sherman , Chief Executive Officer and Mike
Feb 24, 2022 Chimerix, in Collaboration with the Rapidly Emerging Antiviral Drug Development Initiative (READDI) at the University of North Carolina-Chapel Hill, Announces Late-Breaking Oral Presentation at International Conference on Antiviral Research
CMX521 Significantly Reduced Lung Viral Titer and Clinical Symptoms in a SARS-CoV-2 Mouse Model DURHAM, N.C. , Feb. 24, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), in collaboration with the Rapidly Emerging Antiviral Drug Development Initiative at the University of North Carolina at Chapel
Feb 22, 2022 Chimerix to Report Fourth Quarter and Year End 2021 Financial Results and Provide an Operational Update on March 1, 2022
DURHAM, N.C. , Feb. 22, 2022 (GLOBE NEWSWIRE) -- Chimerix  (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that it will host a live conference call and audio
Jan 20, 2022 Chimerix to Present at B. Riley Virtual Oncology Conference
DURHAM, N.C. , Jan. 20, 2022 (GLOBE NEWSWIRE) -- Chimerix  (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced Mike Andriole , Chief Business and Financial Officer,
Displaying 1 - 10 of 12
  • Print
  • Email Alerts
  • RSS Feeds
  • Search
  • Share